6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $503M | $60.6B | 0.0% | -7.2% | -$28M | $77M | $34M |
| 2024 | $393M | $64.7B | 0.0% | -15.3% | -$30M | $93M | $50M |
| 2023 | $324M | -$83M | 0.0% | -23.8% | -$41M | $87M | $33M |
| 2022 | $252M | $152000 | 0.0% | -32.5% | -$67M | $81M | $14M |
| 2021 | $203M | -$11M | 0.0% | -22.6% | -$36M | $183000 | $115M |
| 2020 | $188M | -$14M | 0.0% | -4.4% | -$686000 | $12M | $6M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $147M | -$2M | 0.0% | -4.4% | -$3M | $79M | $30M |
| Dec '25 | $142M | -$8M | 0.0% | -4.9% | $2M | $77M | $34M |
| Sep '25 | $137M | -$17M | 0.0% | -5.9% | -$13M | $76M | $28M |
| Jun '25 | $120M | -$17M | 0.0% | -9.4% | -$11M | $75M | $30M |
| Mar '25 | $104M | -$20M | 0.0% | -9.5% | -$5M | $74M | $40M |
| Dec '24 | $100M | -$13M | 0.0% | -11.9% | $2M | $93M | $50M |
| Sep '24 | $100M | -$16M | 0.0% | -13.9% | $1M | $92M | $47M |
| Jun '24 | $99M | -$15M | 0.0% | -16.6% | -$17M | $90M | $36M |
| Mar '24 | $95M | -$20M | 0.0% | -19.0% | -$16M | $88M | $36M |
| Dec '23 | $86M | -$19M | 0.0% | -17.8% | -$5M | $87M | $33M |
| Sep '23 | $82M | -$17M | 0.0% | -17.0% | -$9M | $85M | $28M |
| Jun '23 | $80M | -$17M | 0.0% | -18.6% | -$10M | $84M | $29M |
| Mar '23 | $76M | -$30M | 0.0% | -43.1% | -$17M | $82M | $15M |
| Dec '22 | $71M | -$11M | 0.0% | -35.1% | -$16M | $81M | $14M |
| Sep '22 | $65M | -$3M | 0.0% | -30.9% | -$22M | $79M | $61M |
| Jun '22 | $61M | -$5M | 0.0% | -30.0% | -$12M | — | $64M |
| Mar '22 | $55M | $19M | 0.0% | -33.5% | -$18M | — | $96M |
| Dec '21 | $52M | -$10M | 0.0% | -78.1% | -$24M | $183000 | $115M |
| Sep '21 | $52M | -$3M | 0.0% | -4.1% | -$4M | — | $12M |
| Jun '21 | $50M | $3M | 0.0% | -2.2% | -$8M | — | $15M |
How the market has priced TOI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Oncology Institute, Inc.'s revenue has grown 21.8% per year. These are computed facts, not advice.
As of FY2025, Oncology Institute, Inc. reported $77M of total debt against $34M of cash; operating income covered interest expense -3.2×.
In FY2025, gross margin was —, operating margin -7.2%, and net margin 12055.4%.
As of Jun '26, Oncology Institute, Inc. traded at a price-to-earnings ratio of about 1332.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.